Key regions: Germany, India, United Kingdom, China, Canada
The demand for oncology drugs in Indonesia has been steadily increasing over the past few years.
Customer preferences: Indonesian customers are becoming more aware of the importance of early detection and treatment of cancer. As a result, they are more willing to invest in expensive oncology drugs that offer higher chances of successful treatment. Additionally, there is a growing preference for targeted therapies that are more effective and have fewer side effects.
Trends in the market: One of the major trends in the Indonesian oncology drugs market is the increasing number of cancer cases. This has led to a rise in demand for chemotherapy drugs, immunotherapy drugs, and targeted therapies. Additionally, there is a growing trend towards the use of biosimilars, which are cheaper alternatives to branded oncology drugs. The Indonesian government has also been taking steps to improve access to oncology drugs by increasing the number of public hospitals and clinics that offer cancer treatment.
Local special circumstances: Indonesia is the fourth most populous country in the world, with a large and growing middle class. This has led to an increase in demand for healthcare services, including oncology drugs. However, there are still significant challenges in the Indonesian healthcare system, such as limited access to healthcare in rural areas and a shortage of trained healthcare professionals.
Underlying macroeconomic factors: The Indonesian economy has been growing steadily over the past few years, with a GDP growth rate of around 5% in 2019. This has led to an increase in disposable income and a growing middle class, which has contributed to the demand for healthcare services. Additionally, the Indonesian government has been investing in infrastructure and healthcare, which has helped to improve access to oncology drugs. However, there are still challenges in the Indonesian healthcare system, such as limited access to healthcare in rural areas and a shortage of trained healthcare professionals.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
